In many solid cancers, PD-1 is upregulated by a large proportion of TILs, whereas its ligands PD-L1 and PD-L2 are expressed by a variety of tumor cells [28–30] and cause a reduction in anti-tumor immunity. Here, PDCD1LG2 is linked to neoplasm.